Valion Bio, Inc. (VBIO) stock
VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.53+0.02 (+4.05%)
Close on Nov 13, 2026Market cap $2.20MP/E –Yield –
Earnings
Valion Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q1 FY2026
–
EPS, Q1 FY2026
-$2.23
-$2.52 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Valion Bio's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026after the close | – | – | -$2.23 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 25, 2026after the close | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 14, 2025after the close | $146.00K | +15.9% | -$1.97 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025after the close | $86.00K | -38.6% | -$2.19 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 15, 2025after the close | – | – | -$2.52 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 21, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024after the close | $126.00K | -55.3% | -$0.23 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024after the close | $140.00K | -13.0% | -$0.32 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 25, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023after the close | $282.00K | -40.9% | -$1.48 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023after the close | $161.00K | -69.5% | -$0.07 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023after the close | $376.00K | -12.1% | -$0.11 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 31, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | $477.00K | – | -$0.27 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022before the open | $528.00K | – | -$0.32 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022before the open | $428.00K | – | -$0.23 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Valion Bio has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Valion Bio puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Valion Bio filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
- News
- News
- Update
- Update
- Update
- Update
- Results
- Update
- Results
See a number that looks wrong?